HERA R&D Introduction
Good quality research and development (R&D) is crucial to the long-term success of the pharmaceutical industry and more generally, the wider life-sciences sector.
R&D refers to the investigative activities a business conducts to improve existing products and procedures or to lead to the development of new products and procedures.
We were see tremendous value in investing in research & development (R&D). Our early investments in R&D, beginning three years ago, enabled us to make technology our key differentiator and develop a line products for diverse markets across the country. Our core strength lies in our ability to excel in developing generics and technologically complex products through focused teams in formulations, manufacturing process and analytical development.
We have around 11 research scientists working in R&D centres equipped with cutting-edge enabling technologies for research. Our scientists have expertise in developing generics pharmaceutical product, difficult to make technology intensive products. Our research strategy and implementation are well supported by a strong intellectual property team having expertise and experience in pharmaceutical development, analytical techniques, dosage forms.
Our production technology is focused on pharmaceuticals in solid forms, including tablet, film-coated tablet, hard gelatine capsule, granules/powder for oral. Our capabilities span the development of differentiated products, such as oncology product, besides developing controlled release dosage forms.
Our scientists work closely with our business development team to generate innovative concepts and ideas, exploiting both market needs and synergies across therapeutic areas.
Even as we focus on developing new technologies, we continuously monitor research efficiency. We have the capability to deliver quality products within established timelines, at low costs and without compromising on quality.